Is Biotech Entering a Time of Stability? These Leaders Say Signs Point to Yes.
January 23, 2026
In a conversation with Boston Business Journal after the J.P. Morgan Healthcare Conference, Jeffrey Quillen, co-chair of the firm’s Life Sciences Industry Group, discussed the state of the biotech industry heading into 2026.
Quillen noted an upturn in financings and M&A activity in the fourth quarter of 2025 and was optimistic that the momentum would continue into 2026: “Does this have legs? Is this likely to carry into the year? I think it does,” he said. Quillen also said that challenging conditions for the industry over previous years weeded out weaker companies, resulting in emerging companies of “really high quality.”
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
